The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6-Reference-Cited by-同舟云学术

The STAT3 inhibitor stattic overcome bortezomib-resistance in multiple myeloma via decreasing PSMB6

Published:2023-08 Issue:1 Volume:429 Page:113634
ISSN:0014-4827
Container-title:Experimental Cell Research
language:en
Short-container-title:Experimental Cell Research

Author:

Yuan Canli,Yuan Mei,Li Wenyu^ORCID,Cheng Hai,Luo Jianping,Zhang Qi,Shi Mengya,Niu Mingshan,Yang Jiajia,Sun Zengtian,Yan Zhiling,Xu Kailin,Li Zhenyu,Yao Yao^ORCID

Publisher

Elsevier BV

Subject

Cell Biology

Reference33 articles.

1. Proteasome inhibitors in multiple myeloma: 10 years later;Moreau;Blood,2012

2. Bortezomib (PS-341): a novel, first-in-class proteasome inhibitor for the treatment of multiple myeloma and other cancers;Richardson;Cancer Control,2003

3. Interferon-gamma-induced upregulation of immunoproteasome subunit assembly overcomes bortezomib resistance in human hematological cell lines;Niewerth;J. Hematol. Oncol.,2014

4. Importance of the different proteolytic sites of the proteasome and the efficacy of inhibitors varies with the protein substrate;Kisselev;J. Biol. Chem.,2006

5. Proteasome inhibition with bortezomib (PS-341): a phase I study with pharmacodynamic end points using a day 1 and day 4 schedule in a 14-day cycle;Hamilton;J. Clin. Oncol.,2005

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation, functional impact, and therapeutic targeting of APOBEC3A in cancer;DNA Repair;2024-09

2. The ERK1/2-Elk1, JNK-cJun, and JAK-STAT Transcriptional Axes as Potential Bortezomib Resistance Mediators in Prostate Cancer;2024-04-20

3. Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells;Frontiers in Pharmacology;2024-03-04